BRIEF published on 03/10/2026 at 09:05, 4 months 29 days ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 4 months 29 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics réalise une levée de fonds de près de 1,7 million d'euros pour développer des thérapies géniques innovantes. Annonce de succès pour l'opération Biopharmaceutique Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
PRESS RELEASE published on 03/10/2026 at 09:00, 4 months 29 days ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 4 months 30 days ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 4 months 30 days ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
BRIEF published on 03/09/2026 at 07:35, 4 months 30 days ago GenSight Biologics : Point sur les Programmes d'Accès Précoce et l'Étude REVISE Thérapie Génique GenSight Biologics Neuropathie Optique Étude REVISE Accès Précoce
BRIEF published on 03/09/2026 at 07:35, 4 months 30 days ago GenSight Biologics fait le point sur ses programmes d'accès précoce et l'étude REVISE GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ® Étude REVISER Programmes D'accès Anticipé
PRESS RELEASE published on 03/09/2026 at 07:30, 4 months 30 days ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
PRESS RELEASE published on 03/09/2026 at 07:30, 4 months 30 days ago Informations privilégiées / Autres communiqués GenSight Biologics fait le point sur les programmes d'accès précoce de GS010/LUMEVOQ et sur l'étude REVISE en cours, avec des approbations en France, Israël et aux États-Unis Thérapie Génique GenSight Biologics GS010/LUMEVOQ Accès Précoce Dose REVISE
BRIEF published on 02/18/2026 at 07:35, 5 months 18 days ago GenSight Biologics renforce son leadership réglementaire grâce à des nominations clés Thérapie Génique GenSight Biologics Maladies De La Rétine Nominations Stratégiques Leadership Réglementaire
Published on 08/07/2026 at 23:15, 17 hours 33 minutes ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 17 hours 48 minutes ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 18 hours 18 minutes ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 18 hours 33 minutes ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/08/2026 at 16:25, 23 minutes ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 17 hours 27 minutes ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 21 hours 18 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 21 hours 33 minutes ago ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 22 hours 38 minutes ago Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:54, 21 hours 54 minutes ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 21 hours 54 minutes ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 22 hours 8 minutes ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 22 hours 8 minutes ago Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 22 hours 48 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026
